Revolutionizing Vaccine Development

Self-amplifying RNA (saRNA)

Rapid response to emerging diseases is critical when developing a vaccine. Synthetic RNA platforms (mRNA and saRNA) are at the forefront of novel vaccine development programs.

Benefits of saRNA

• saRNA vaccines can be developed in a fraction of the time it takes to develop a conventional vaccine¹
• Manufacturing is cell-free, does not require a dedicated facility
• saRNA vaccines often produce a higher immune response from a smaller dose when compared to mRNA based vaccines²

Note: saRNA products are classified by Aldevron under ECCN 1C353 on the Commerce Control List set forth in the US Export Administration Regulations (EAR), which is highly controlled for purposes of export outside the United States. If the product is requested to be shipped outside the US, an export license from US Dept. of Commerce’s Bureau of Industry and Security is required before the product may be shipped.

Learn More >

¹Bloom, K., van den Berg, F. & Arbuthnot, P., 2020. Self-amplifying RNA vaccines for infectious diseases. Gene therapy.

²Vogel, A.B. et al., 2018. Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. Molecular therapy: the journal of the American Society of Gene Therapy, 26(2), pp.446–455.